Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.31 |
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.31 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.30 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.30 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.30 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.30 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20029214 | 0.74 | BMPR1B (0.46) | ACVR1MAPKAPK5BMPR1BKDRBMPR1A | |
| SCHEMBL22324845 | 0.74 | GRM2 (0.44) | ACVR1MAPKAPK5BMPR1BKDRBMPR1A | |
| SCHEMBL22324843 | 0.72 | GRM2 (0.37) | ACVR1 | |
| SCHEMBL22340466 | 0.72 | DHFR (0.46) | — | |
| SCHEMBL11922651 | 0.72 | CHKA (0.41) | CHRNB2CHRNA4HRH3 | |
| SCHEMBL14336874 | 0.71 | LMNA (0.52) | CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL7496180 | 0.70 | ROCK2 (0.40) | CHRNB2CHRNA4HRH3 | |
| SCHEMBL25181538 | 0.70 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL22324860 | 0.70 | DRD2 (0.44) | — | |
| SCHEMBL22324798 | 0.70 | SLC18A3 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539849-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250121070-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2023244764-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023244764-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250121070-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | SMARCA2, SMARCE1, SMARCA1 | CHRNB2 937/4885CHRNB4 1142/4885CHRNA3 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.